CPMG Inc

Q4 2017 13F Holdings Report, Restatement, Stock Holdings

Signature - Title
John E. Bateman - Chief Operating Officer
Location
Dallas
Holdings as of
31 Dec 2017
Value $
$989,237,245
Num holdings
17
Filing time
02 Oct 2018, 16:16:16 UTC
Form type
13F-HR/A-1 - Restatement
Description
All US holdings of this investor are reported in this report. Top holdings included ISRG, URI, RETA, KL, and GSSXXXX.
Next filing
Q1 2018 - 02 Oct 2018
SEC
View on sec.gov
Options Holdings
Showing stock holdings, see here for options holdings
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
John E. Bateman Chief Operating Officer Dallas, Texas 02 Oct 2018

This Amendment Number 1 is being filed to restate the position information in Reata Pharmaceuticals, Inc. ("Reata"). The Form 13F-HR filed on February 14, 2018 inadvertently reported the position information for Reata as the total of Class A and Class B shares over which CPMG, Inc. ("CPMG") had investment discretion as of December 31, 2017. This Amendment Number 1 includes only the reportable 2,912,523 Class A shares over which CPMG had investment discretion as of December 31, 2017. This Amendment Number 1 does not include the 1,692,857 Class B shares of Reata over which CPMG had investment discretion as of December 31, 2017 because such Class B shares were not included in the relevant quarter's Official List of Section 13(f) Securities, and thus should be excluded.